Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Gains from Investment Securities: 2018-2024

Historic Gains from Investment Securities for Eton Pharmaceuticals (ETON) over the last 7 years, with Dec 2024 value amounting to $5.9 million.

  • Eton Pharmaceuticals' Gains from Investment Securities fell 84.36% to $28,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 321.26%. This contributed to the annual value of $5.9 million for FY2024, which is 22.31% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Gains from Investment Securities stood at $5.9 million for FY2024, which was up 22.31% from $4.8 million recorded in FY2023.
  • In the past 5 years, Eton Pharmaceuticals' Gains from Investment Securities registered a high of $5.9 million during FY2024, and its lowest value of $181,000 during FY2021.
  • In the last 3 years, Eton Pharmaceuticals' Gains from Investment Securities had a median value of $4.8 million in 2023 and averaged $5.1 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 89.34% in 2020, then soared by 2,332.21% in 2022.
  • Eton Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $195,000 in 2020, then dropped by 7.18% to $181,000 in 2021, then skyrocketed by 2,332.21% to $4.4 million in 2022, then increased by 9.93% to $4.8 million in 2023, then grew by 22.31% to $5.9 million in 2024.